Vera Therapeutics, Inc. (VERA)

NGM – Real Time Price. Currency in USD

36.70

+0.09 (0.25%)

At close: May 12, 2026, 4:00 PM EDT

36.78

+0.08 (0.22%)

After-hours: May 12, 2026, 7:52 PM EDT

08.05.2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 40,250 shares of Class A common stock and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

07.05.2026

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 On track for U.S. commercial launch of atacicept in mid-2026, pending regulatory approval Strong balance sheet expected to be sufficient to fund operations beyond potential atacicept approval and U.S. commercial launch BRISBANE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2026.

04.05.2026

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026.

10.04.2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares of Class A common stock and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock to eighty-nine (89) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

01.04.2026

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.

27.03.2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 56,850 shares of Class A common stock and restricted stock units (RSUs) underlying 42,403 shares of Class A common stock to Jane Wright-Mitchell, Vera's new Chief Legal Officer under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

25.03.2026

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D.

Videos

No Data

There is no data to display

Press releases

08.05.2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07.05.2026

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

04.05.2026

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

10.04.2026

Vera Therapeutics, Inc. (VERA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vera Therapeutics, Inc. (VERA)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Videos

No Data

Press releases

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Videos

No Data

Press releases

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Vera Therapeutics, Inc. (VERA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Vera Therapeutics, Inc. (VERA)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Videos

No Data

Press releases

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Videos

No Data

Press releases

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)